source
- Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drugWerewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and raised $150 million, positioning the biotech to take…Fierce Biotech · 5h ago↗ source
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…
- Regeneron secures FDA approval for Pasatru, second U.S. treatment for rare bone disease FOP